IRIS Accounts Production v26.1.10.61 06873208 Board of Directors Board of Directors 1.5.25 30.4.26 30.4.26 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh068732082025-04-30068732082026-04-30068732082025-05-012026-04-30068732082024-04-30068732082024-05-012025-04-30068732082025-04-3006873208ns15:EnglandWales2025-05-012026-04-3006873208ns14:PoundSterling2025-05-012026-04-3006873208ns10:Director12025-05-012026-04-3006873208ns10:Director22025-05-012026-04-3006873208ns10:PrivateLimitedCompanyLtd2025-05-012026-04-3006873208ns10:SmallEntities2025-05-012026-04-3006873208ns10:AuditExempt-NoAccountantsReport2025-05-012026-04-3006873208ns10:SmallCompaniesRegimeForDirectorsReport2025-05-012026-04-3006873208ns10:SmallCompaniesRegimeForAccounts2025-05-012026-04-3006873208ns10:FullAccounts2025-05-012026-04-3006873208ns10:CompanySecretary12025-05-012026-04-3006873208ns10:RegisteredOffice2025-05-012026-04-3006873208ns5:CurrentFinancialInstruments2026-04-3006873208ns5:CurrentFinancialInstruments2025-04-3006873208ns5:ShareCapital2026-04-3006873208ns5:ShareCapital2025-04-3006873208ns5:RetainedEarningsAccumulatedLosses2026-04-3006873208ns5:RetainedEarningsAccumulatedLosses2025-04-3006873208ns5:LongLeaseholdAssetsns5:LandBuildings2025-05-012026-04-3006873208ns5:PlantMachinery2025-05-012026-04-3006873208ns5:FurnitureFittings2025-05-012026-04-3006873208ns5:ComputerEquipment2025-05-012026-04-3006873208ns5:LongLeaseholdAssetsns5:LandBuildings2025-04-3006873208ns5:PlantMachinery2025-04-3006873208ns5:FurnitureFittings2025-04-3006873208ns5:ComputerEquipment2025-04-3006873208ns5:LongLeaseholdAssetsns5:LandBuildings2026-04-3006873208ns5:PlantMachinery2026-04-3006873208ns5:FurnitureFittings2026-04-3006873208ns5:ComputerEquipment2026-04-3006873208ns5:LongLeaseholdAssetsns5:LandBuildings2025-04-3006873208ns5:PlantMachinery2025-04-3006873208ns5:FurnitureFittings2025-04-3006873208ns5:ComputerEquipment2025-04-3006873208ns5:WithinOneYearns5:CurrentFinancialInstruments2026-04-3006873208ns5:WithinOneYearns5:CurrentFinancialInstruments2025-04-3006873208ns10:Director112025-04-3006873208ns10:Director112024-04-3006873208ns10:Director112025-05-012026-04-3006873208ns10:Director112024-05-012025-04-3006873208ns10:Director112026-04-3006873208ns10:Director112025-04-30068732082ns10:Director22025-04-30068732082ns10:Director22024-04-30068732082ns10:Director22025-05-012026-04-30068732082ns10:Director22024-05-012025-04-30068732082ns10:Director22026-04-30068732082ns10:Director22025-04-300687320812025-05-012026-04-30
REGISTERED NUMBER: 06873208 (England and Wales)















Unaudited Financial Statements

for the Year Ended

30 April 2026

for

Molecular Trading Limited

Molecular Trading Limited (Registered number: 06873208)

Contents of the Financial Statements
for the Year Ended 30 April 2026










Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


Molecular Trading Limited

Company Information
for the Year Ended 30 April 2026







DIRECTORS: G B Costello
Mrs J Banks





SECRETARY:





REGISTERED OFFICE: 1A Castle Farm Lane
Great Moore
Stockport
Cheshire
SK2 7PU





REGISTERED NUMBER: 06873208 (England and Wales)





ACCOUNTANTS: TF & Partners Ltd t/a Hatherlows
Chartered Accountants
The Studio, Hatherlow House
Hatherlow
Romiley
Stockport
Cheshire
SK6 3DY

Molecular Trading Limited (Registered number: 06873208)

Statement of Financial Position
30 April 2026

2026 2025
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 5 3,709 3,121

CURRENT ASSETS
Stocks - 86,273
Debtors 6 25,039 82,460
Cash at bank 180,312 59,508
205,351 228,241
CREDITORS
Amounts falling due within one year 7 67,526 78,545
NET CURRENT ASSETS 137,825 149,696
TOTAL ASSETS LESS CURRENT
LIABILITIES

141,534

152,817

CAPITAL AND RESERVES
Called up share capital 3 3
Retained earnings 141,531 152,814
141,534 152,817

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Molecular Trading Limited (Registered number: 06873208)

Statement of Financial Position - continued
30 April 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 August 2026 and were signed on its behalf by:




Mrs J Banks - Director



G B Costello - Director


Molecular Trading Limited (Registered number: 06873208)

Notes to the Financial Statements
for the Year Ended 30 April 2026


1. STATUTORY INFORMATION

Molecular Trading Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Long leasehold - 10% on cost
Plant and machinery - 33% on cost
Fixtures and fittings - 15% on reducing balance
Computer equipment - 33% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Molecular Trading Limited (Registered number: 06873208)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2026


4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2025 - 2 ) .

5. TANGIBLE FIXED ASSETS
Fixtures
Long Plant and and Computer
leasehold machinery fittings equipment Totals
£    £    £    £    £   
COST
At 1 May 2025 14,200 2,151 - 3,822 20,173
Additions - - 1,065 1,133 2,198
At 30 April 2026 14,200 2,151 1,065 4,955 22,371
DEPRECIATION
At 1 May 2025 14,200 2,151 - 701 17,052
Charge for year - - 119 1,491 1,610
At 30 April 2026 14,200 2,151 119 2,192 18,662
NET BOOK VALUE
At 30 April 2026 - - 946 2,763 3,709
At 30 April 2025 - - - 3,121 3,121

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade debtors 25,039 -
Other debtors - 82,460
25,039 82,460

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade creditors 23,801 2,264
Taxation and social security 8,415 11,745
Other creditors 35,310 64,536
67,526 78,545

Molecular Trading Limited (Registered number: 06873208)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2026


8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 30 April 2026 and 30 April 2025:

2026 2025
£    £   
Mrs J Banks
Balance outstanding at start of year (20,000 ) (20,000 )
Amounts advanced 4,215 -
Amounts repaid - -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (15,785 ) (20,000 )

G B Costello
Balance outstanding at start of year (40,000 ) (20,000 )
Amounts advanced 24,215 -
Amounts repaid - (20,000 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (15,785 ) (40,000 )

9. RELATED PARTY DISCLOSURES

During the year, total dividends of £47,000 (2025 - £48,000) were paid to the directors .

10. POST BALANCE SHEET EVENTS

The financial statements were authorised for issue by the directors on 28 August 2026.

11. ULTIMATE CONTROLLING PARTY

The controlling party is G B Costello.

The ultimate controlling party is G B Costello.